HUP0402245A2 - Glikogén-szintáz-kináz-3béta inhibitor hatású pirimidinil-aminobenzamid-származékok, alkalmazásuk, ezeket tartalmazó gyógyszerkészítmények és eljárás az előállításukra - Google Patents

Glikogén-szintáz-kináz-3béta inhibitor hatású pirimidinil-aminobenzamid-származékok, alkalmazásuk, ezeket tartalmazó gyógyszerkészítmények és eljárás az előállításukra

Info

Publication number
HUP0402245A2
HUP0402245A2 HU0402245A HUP0402245A HUP0402245A2 HU P0402245 A2 HUP0402245 A2 HU P0402245A2 HU 0402245 A HU0402245 A HU 0402245A HU P0402245 A HUP0402245 A HU P0402245A HU P0402245 A2 HUP0402245 A2 HU P0402245A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
alkynyl
alkenyl
r5r6n
Prior art date
Application number
HU0402245A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Peter Jacobus Johannes Antonius Buijnsters
Marc Willems
Werner Constant Johan Embrechts
Paul Adriaan Jan Janssen
Paulus Joannes Lewi
Jan Heeres
Marc René Jonge
Lucien Maria Henricus Koymans
Frederik Frans Desire Daeyaert
Michael Joseph Kukla
Hugo Alfons Gabriel Geerts
Rony Maria Nuydens
Marc Hubert Mercken
Donald William Ludovici
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HUP0402245A2 publication Critical patent/HUP0402245A2/hu
Publication of HUP0402245A3 publication Critical patent/HUP0402245A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A találmány szerinti vegyületek (I) általános képletében Z jelentéseoxigénatom vagy kénatom, A jelentése piridilcsoport,pirimidinilcsoport, pirazinilcsoport vagy piridazinilcsoport, R1jelentése hidrogénatom, arilcsoport, formilcsoport,alkilkarbonilcsoport, alkilcsoport, alkiloxikarbonilcsoport,formilcsoporttal, alkilkarbonilcsoporttal, alkiloxikarbonilcsoporttalvagy alkilkarboniloxicsoporttal szubsztituált alkilcsoport vagyalkiloxialkilkarbonilcsoport, amely adott esetbenalkiloxikarbonilcsoporttal szubsztituálva lehet, X jelentése -NR1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -C(=S)-, -O-C(=O)-, -C(=O)-O-, -O-C(=O-(alkil)-, -C(=O)-O-(alkil)-, -O-(alkil)-C(=O)-, -C(=O)-(alkil)-O-, -O-C(=)NR1-, -NR1-C(=O)-O-, -O-C(=O)-C(=O)-, -C(=O)-NR1-, -NR1-C(=O)-, -C(=S)-NR1-, -NR1-C(=S)-, -NR1-C(=O)-NR1-, -NR1-C(=S)-NR1-, -NR1-S(=O)-NR1-, -NR1S(=O)2-NR1-, -(alkil)-C(=O)-NR1-, -O-(alkil)-C(=O)-NR1-, -(alkil)-O-C(=O)-NR1-, -(alkil)-, -O-(alkil)-, -(alkil)-O-, -NR1-(alkil)-, -(alkil)-NR1-, -NR1-(alkil)-NR1-, -NR1(alkil)-(cikloalkil)-,-(alkenil)-, -(alkinil)-, -O-(alkenil)-, -(alkenil)-O-, -NR1-(alkenil)-, -(alkenil)-NR1-, -NR1-(alkenil)-NR1-, -NR1-(alkenil)-(cikloalkil)-, -O-(alkinil)-, -(alkinil)-O-, -NR1-(alkinil)-, -(alkinil)-NR1-, -NR1-(alkinil)-NR1-, -NR1-(alkinil)(cikloalkil)-, -O-(alkil)-O-, -O-(alkenil)-O-, -O-(alkinil)-O-, -CHOH-, -S-, -S(=O)-, -S(=O)2-, -S(=O)-NR1-, -S(=O)2-NR1-, -NR1-S(=O)-, -NR1S(=O)2-; -S-(alkil)-, -(alkil)-S-, -S-(alkenil)-, -(alkenil)-S-, -S-(alkinil)-, -(alkinil)-S- vagy -O-(alkil)-S(=O)2- képletű csoport vagy közvetlenkötés, R2 jelentése hidrogénatom, alkilcsoport, alkenilcsoport,alkinilcsoport vagy R20, amelyek egyenként adott esetben egy vagy többazonos vagy különböző szubsztituenssel szubsztituálva lehetnek, ahol aszubsztituens =S, =O, R15, hidroxilcsoport, halogénatom, nitrocsoport,cianocsoport, R15-O-, SH, R15-S-, formilcsoport, karboxilcsoport, R15-C(=O)-, R15-O-C(=O)-, R15-C(=O)-O-, R15-O-C(=O)O-, -SO3H, R15-S-(=O)-,R15-S(=O)2-, R5R6N, R5R6N-(alkil)-, R5R6N-(cikloalkil)-, R5R6N-(alkoxi)-, R5R6N-C(=O)-, R5R6N-C(=S)-, R5R6N-C(=O)-NH-, R5R6N-C(=S)NH-, R5R6N-S(=O)n-, R5R6N-S(=O)n-NH-, R15-C(=S)- R15-C(=O)-NH-,R15-OC(=O)-NH-, R15-S(=O)n-NH-, R15-O-S(=O)n-NH-, R15-C(=S)-NH-, R15-O-C(=S)-NH-, R17R18N-Y1a-, R17R18N-Y2-NR16-Y1, R15-Y2-NR19-Y1, vagy H-Y2-NR19-Y1 képletű csoport, R3 jelentése hidrogénatom,hidroxilcsoport, halogénatom, alkilcsoport, cianocsoporttal,hidroxilcsoporttal vagy -C(=O)-R7 képletű csoporttal szubsztituáltalkilcsoport, alkenilcsoport, egy vagy több halogénatommal vagycianocsoporttal szubsztituált alkenilcsoport, alkinilcsoport, egy vagytöbb halogénatommal vagy cianocsoporttal szubsztituált alkinilcsoport,alkiloxicsoport, alkiltiocsoport, alkiloxikarbonilcsoport,alkilkarboniloxicsoport, karboxilcsoport, cianocsoport, n
HU0402245A 2001-11-01 2002-10-29 Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them HUP0402245A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204192 2001-11-01
PCT/EP2002/012079 WO2003037877A1 (en) 2001-11-01 2002-10-29 AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS

Publications (2)

Publication Number Publication Date
HUP0402245A2 true HUP0402245A2 (hu) 2005-02-28
HUP0402245A3 HUP0402245A3 (en) 2010-03-29

Family

ID=8181175

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402245A HUP0402245A3 (en) 2001-11-01 2002-10-29 Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them

Country Status (21)

Country Link
US (1) US20060063789A1 (hu)
EP (1) EP1442024B1 (hu)
JP (1) JP2005507420A (hu)
KR (1) KR20040062557A (hu)
CN (1) CN100436427C (hu)
AT (1) ATE389638T1 (hu)
AU (1) AU2002363177B2 (hu)
BR (1) BR0213790A (hu)
CA (1) CA2463823A1 (hu)
DE (1) DE60225709T2 (hu)
DK (1) DK1442024T3 (hu)
EA (1) EA007063B1 (hu)
ES (1) ES2303565T3 (hu)
HU (1) HUP0402245A3 (hu)
IL (1) IL161663A0 (hu)
MX (1) MXPA04004176A (hu)
NO (1) NO326889B1 (hu)
NZ (1) NZ531854A (hu)
PL (1) PL368920A1 (hu)
PT (1) PT1442024E (hu)
WO (1) WO2003037877A1 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794965B2 (en) 2002-03-13 2010-09-14 Signum Biosciences, Inc. Method of identifying modulators of PP2A methylase
AU2003288198A1 (en) * 2002-11-28 2004-06-18 Schering Aktiengesellschaft CHK-,PDK- and AKT-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10322911A1 (de) * 2003-05-21 2004-12-16 Bayer Materialscience Ag Verfestigungsstabile blockierte Polyisocyanate
MXPA06001759A (es) * 2003-08-15 2006-05-12 Novartis Ag 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios.
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2214486A4 (en) * 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2789711C (en) * 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348961B (es) 2011-02-18 2017-07-04 Asana Biosciences Llc Compuestos de aminoindano y su uso en el tratamiento del dolor.
BR112013024378A2 (pt) 2011-03-24 2016-12-13 Chemilia Ab novos derivados de pirimidina
TWI603957B (zh) 2012-08-15 2017-11-01 阿沙納生物科學有限責任公司 胺基氫茚化合物用於治療膀胱過動症及間質性膀胱炎之用途
WO2014031784A1 (en) 2012-08-23 2014-02-27 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP3092233A1 (en) 2014-01-10 2016-11-16 Glaxosmithkline Intellectual Property (No. 2) Limited Hydroxy formamide derivatives and their use
WO2017156527A1 (en) * 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
CN106632021A (zh) * 2016-09-27 2017-05-10 中国药科大学 2‑取代异烟酸类化合物、其制备方法及其用途
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN112876420B (zh) * 2019-11-29 2023-01-24 沈阳化工研究院有限公司 一种硫代苯甲酰衍生物及其应用
WO2021155185A1 (en) * 2020-01-30 2021-08-05 Sumitomo Dainippon Pharma Oncology, Inc. Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
CN114105887B (zh) * 2021-09-16 2023-12-01 沈阳药科大学 一种氨基嘧啶衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) * 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
EP0162204A3 (de) * 1984-05-22 1988-07-06 Franz Grimme Landmaschinenfabrik GmbH & Co. KG. Riemenschloss für Riemen von Siebkettenförderbändern
EP0233461B2 (en) * 1986-01-13 2002-05-29 American Cyanamid Company 4,5,6-Substituted-2-pyrimidinamines
US4966622A (en) * 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
HU230522B1 (hu) * 1998-03-27 2016-10-28 Janssen Pharmaceutica N.V HIV-gátló pirimidinszármazékok
CN1312807A (zh) * 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
PL214667B1 (pl) * 2000-12-21 2013-08-30 Glaxo Group Ltd Pochodne pirydynoaminy, srodek farmaceutyczny i zastosowanie pochodnych pirymidynoaminy do wytwarzania leku
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003032997A1 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
EP1442024B1 (en) 2008-03-19
CA2463823A1 (en) 2003-05-08
CN1703405A (zh) 2005-11-30
US20060063789A1 (en) 2006-03-23
EP1442024A1 (en) 2004-08-04
ES2303565T3 (es) 2008-08-16
NZ531854A (en) 2006-03-31
DE60225709D1 (de) 2008-04-30
ATE389638T1 (de) 2008-04-15
IL161663A0 (en) 2004-09-27
AU2002363177B2 (en) 2008-09-18
DK1442024T3 (da) 2008-06-30
EA200400616A1 (ru) 2004-08-26
NO326889B1 (no) 2009-03-16
WO2003037877A1 (en) 2003-05-08
DE60225709T2 (de) 2009-05-07
CN100436427C (zh) 2008-11-26
BR0213790A (pt) 2004-12-07
NO20042253L (no) 2004-06-01
PL368920A1 (en) 2005-04-04
HUP0402245A3 (en) 2010-03-29
PT1442024E (pt) 2008-06-12
EA007063B1 (ru) 2006-06-30
MXPA04004176A (es) 2004-09-06
JP2005507420A (ja) 2005-03-17
KR20040062557A (ko) 2004-07-07

Similar Documents

Publication Publication Date Title
HUP0402245A2 (hu) Glikogén-szintáz-kináz-3béta inhibitor hatású pirimidinil-aminobenzamid-származékok, alkalmazásuk, ezeket tartalmazó gyógyszerkészítmények és eljárás az előállításukra
HUP0402106A2 (hu) Glikogén-szintáz-kináz-3-béta inhibitor hatású heteroaril-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402330A2 (hu) Glikogén-szintáz-kináz-3-béta inhibitor hatású amidszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402171A2 (hu) PDE7 inhibitor hatással rendelkező pirazolopirimidinon-származékok
HUP0300927A2 (hu) Új pirimidinszármazékok és ezeket tartalmazó defekációt elősegítő gyógyszerkészítmények
TW200942541A (en) Polysubstituted 6-heteroarylimidazo[1,2-α]pyridine derivatives, preparation thereof and therapeutic use thereof
RS52990B (en) 1H BENZIMIDAZOL-4-CARBOXAMIDES SUBSTITUTED WITH QUATERNER CARBON IN POSITION-2 AS INHIBITORS FOR USE IN CANCER TREATMENT
EA200900593A1 (ru) Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
ATE480239T1 (de) Angiogeneseinhibitoren
NO20071234L (no) Forbindelser som potensierer glutamatreseptor og anvendelse derav innen medisin
RS52166B (en) AMINO-HETEROCYCLIC COMPOUNDS
CY1111069T1 (el) Παραγωγα διυδροπυραζολοπυριμιδινονης
CY1110232T1 (el) Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
DK0751930T3 (da) Amidinoderivater anvendelige som nitrogenoxid-synthase-inhibitorer
HUP0102360A2 (hu) 1,3-Oxazolin- és 1,3-tiazolin-származékok, eljárás a vegyületek előállítására és peszticidként történő alkalmazásuk
HRP20050628A2 (en) Substituted benzoyl derivatives uses as herbicides
RS52964B (en) 7-PIPERIDINOALKIL-3,4-DIHYDROKVINOLONE DERIVATIVE
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
ATE512154T1 (de) Kondensiertes pyrimidinderivat und xanthinoxidaseinhibitor
AR066606A1 (es) Compuestos de heteroarilamida pirimidona
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
TW200602344A (en) Novel pyrrolo(2, 3-b)pyridine derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CO4990960A1 (es) Derivados de cetolidos 2-halo-6-o sustituidos
BR0308759A (pt) Derivados de fenil amidas siliconadas utilizáveis como microbiocida
HUP0003219A2 (hu) Ftalazinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása erekciós diszfunkció kezelésére alkalmas gyógyászati készítmények előállítására

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished